Cemiplimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Melanoma · Phase 3

Also approved (5)
US
  • Adjuvant treatment of patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiationFDA label
  • LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation; for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. Basal Cell Carcinoma (BCC) for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. Non-Small Cell Lung Cancer (NSCLC) in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic; as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic.
    FDA label
Product first approved 2018Outside this platform's coverage
JP
  • Treatment of advanced or recurrent cervical cancer that has progressed after cancer chemotherapy
Product first approved 2022PMDA
EU
  • Cutaneous Squamous Cell Carcinoma Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation (see section 5.1 for selection criteria). Basal Cell Carcinoma Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell...
Product first approved 2019Outside this platform's coverageEMA
CA
  • Cutaneous Squamous Cell Carcinoma LIBTAYO (cemiplimab for injection) is indicated for: • the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. • the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. Non-Small Cell Lung Cancer LIBTAYO (cemiplimab for injection) is indicated: • as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells...
Product first approved 2019Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Melanoma
NCT06246916 · Regeneron Pharmaceuticals
2024-09-09 – 2033-07-10 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07943325 · Goethe University
2027-02 – 2032-02 · Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT06931717 · ETOP IBCSG Partners Foundation
2026-01-12 – 2029-03 · Non-Small Cell Lung Cancer
What this study did
NCT06908304 · Maia Biotechnology
2025-12-08 – 2027-12-31 · Carcinoma, Non-Small -Cell Lung
What this study did
NCT03515629 · Regeneron Pharmaceuticals
2018-07-02 – 2021-07-29 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06568172 · National Cancer Institute (NCI)
2025-02-18 – 2031-08-14 · Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
What this study did
NCT06585410 · Regeneron Pharmaceuticals
2025-01-02 – 2030-05-03 · Cutaneous Squamous Cell Carcinoma (CSCC)
What this study did
NCT03969004 · Regeneron Pharmaceuticals
2019-06-04 – 2028-01-07 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT03257267 · Regeneron Pharmaceuticals
2017-09-05 – 2023-04-20 · Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
What this study did
Phase 2/3 (3)
Non-Small Cell Lung Cancer
NCT05800015 · Regeneron Pharmaceuticals
2023-08-08 – 2031-12-23 · Non-small Cell Lung Cancer
What this study did
NCT06616584 · SWOG Cancer Research Network
2025-05-22 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT05785767 · Regeneron Pharmaceuticals
2023-06-30 – 2027-09-28 · Advanced Non-Small Cell Lung Cancer
What this study did
Phase 2 (107)
Melanoma
NCT06190951 · Regeneron Pharmaceuticals
2024-09-18 – 2030-12-09 · Melanoma
What this study did
NCT06121180 · H. Lee Moffitt Cancer Center and Research Institute
2024-11-04 – 2030-10-31 · Metastatic Uveal Melanoma
What this study did
NCT06848088 · Regeneron Pharmaceuticals
2025-04-14 – 2030-10-09 · Melanoma
What this study did
NCT07511036 · M.D. Anderson Cancer Center
2026-09-01 – 2030-05-24 · Melanoma
What this study did
NCT07527325 · University of California, Irvine
2026-12 – 2030-02-01 · Melanoma (Skin)
What this study did
NCT06887088 · Grupo Español Multidisciplinar de Melanoma
2025-05-29 – 2028-01 · Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
What this study did
NCT06594991 · Memorial Sloan Kettering Cancer Center
2024-09-10 – 2027-09 · Advanced Melanoma
What this study did
NCT04291105 · Vyriad, Inc.
2020-04-24 – 2026-12 · Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
What this study did
NCT04526899 · BioNTech SE
2021-05-19 – 2025-11-24 · Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07720167 · Medical University of South Carolina
2027-02-01 – 2036-08-01 · Non-Small Cell Lung Cancer
What this study did
NCT06465329 · Regeneron Pharmaceuticals
2024-11-18 – 2034-12-27 · Non Small Cell Lung Cancer, NSCLC
What this study did
NCT06918132 · Mayo Clinic
2025-05-02 – 2033-12-02 · Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT07001618 · Gustave Roussy, Cancer Campus, Grand Paris
2025-11-17 – 2032-09 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06449313 · Georgetown University
2026-11 – 2032-09 · Non-small Cell Lung Cancer Stage III
What this study did
NCT07360743 · UNICANCER
2026-08-21 – 2032-04 · Non Small Cell Lung Cancer (Squamous or Non Squamous)
What this study did
NCT06623656 · Weill Medical College of Cornell University
2025-02-21 – 2032-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06656598 · Intergroupe Francophone de Cancerologie Thoracique
2025-11-07 – 2032-01 · Stage III NSCLC
What this study did
NCT06917573 · Fundación GECP
2025-07-29 – 2031-12-30 · Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Thoracic Neoplasms
What this study did
NCT07746388 · University of Maryland, Baltimore
2026-09-19 – 2031-09-01 · Nsclc, NSCLC Stage II, NSCLC, Stage III, NSCLC Stage IIIB, Resectable Lung Non-Small Cell Carcinoma
What this study did
NCT07418931 · Gruppo Oncologico Italiano di Ricerca Clinica
2026-05 – 2030-11 · Advanced Squamous Non-Small Cell Lung Cancer
What this study did
NCT07274384 · Università Vita-Salute San Raffaele
2026-01-01 – 2030-06-01 · NSCLC (Non-small Cell Lung Cancer), Hyperprogression
What this study did
NCT03916627 · Regeneron Pharmaceuticals
2019-07-23 – 2030-05-14 · Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06219317 · European Organisation for Research and Treatment of Cancer - EORTC
2025-01-14 – 2030-01 · NSCLC Stage IV
What this study did
NCT07808138 · The Netherlands Cancer Institute
2026-11 – 2029-12-01 · Non Small Cell Lung Cancer, Immunotherapy
What this study did
NCT05840770 · City of Hope Medical Center
2025-04-15 – 2029-10-30 · Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
What this study did
NCT06385262 · Duke University
2025-03-17 – 2029-10-30 · Non Small Cell Lung Cancer
What this study did
NCT07264673 · Fondazione Ricerca Traslazionale
2025-04-17 – 2029-10 · NSCLC
What this study did
NCT07946848 · Immuneering Corporation
2026-12 – 2029-07 · NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell Cancer, Locally Advanced Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)
What this study did
NCT05557591 · Regeneron Pharmaceuticals
2023-04-21 – 2028-05-16 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06943664 · Roswell Park Cancer Institute
2026-08-15 – 2028-05-01 · Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT06731270 · Emory University
2025-04-09 – 2028-01-01 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT05208944 · Maia Biotechnology
2022-06-08 – 2027-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07450183 · Henry Ford Health System
2027-01-01 – 2027-12-01 · Lung Cancer (NSCLC)
What this study did
NCT04253964 · Wake Forest University Health Sciences
2020-07-01 – 2027-09-01 · Nonsmall Cell Lung Cancer, Performance Status
What this study did
NCT06865339 · Montefiore Medical Center
2025-08-07 – 2027-08 · NSCLC, Locally Advanced
What this study did
NCT05553834 · Duke University
2023-05-16 – 2026-11-01 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT05401786 · The Netherlands Cancer Institute
2023-01-03 – 2026-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04916002 · Regeneron Pharmaceuticals
2021-11-30 – 2024-10-31 · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
What this study did
Other / comorbidity
NCT07050186 · Northwestern University
2025-08-15 – 2035-11-20 · Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
What this study did
NCT07195734 · National Cancer Institute (NCI)
2026-04-24 – 2033-02-01 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT07620548 · Washington University School of Medicine
2026-11-30 – 2032-11-30 · Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
What this study did
NCT07470489 · M.D. Anderson Cancer Center
2026-10-29 – 2032-09-01 · Anaplastic Thyroid Cancer
What this study did
NCT07433673 · Columbia University
2027-01 – 2032-01 · Colon and Rectal Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07346196 · University of Chicago
2027-02-07 – 2031-08-22 · Squamous Cell Carcinoma
What this study did
NCT07387198 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2026-05-29 – 2031-07-31 · Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy
What this study did
NCT05929664 · Thomas Jefferson University
2023-07-05 – 2031-07-05 · Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
What this study did
NCT07715734 · Washington University School of Medicine
2026-11-30 – 2031-04-30 · Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
What this study did
NCT06769698 · Regeneron Pharmaceuticals
2026-04-14 – 2030-12-28 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
Phase 1/2 (36)
Melanoma
NCT06413680 · Regeneron Pharmaceuticals
2024-09-23 – 2030-02-03 · Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
What this study did
NCT04913220 · Sanofi
2021-07-15 – 2025-02-18 · Malignant Melanoma, Squamous Cell Carcinoma of Skin
What this study did
NCT03684785 · Exicure, Inc.
2018-12-13 – 2022-03-30 · Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors
What this study did
Non-Small Cell Lung Cancer
NCT06088771 · Icahn School of Medicine at Mount Sinai
2024-10-09 – 2027-07-01 · Non-Small Cell Lung Cancer
What this study did
NCT05501665 · Vanderbilt-Ingram Cancer Center
2023-05-09 – 2027-02-01 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
What this study did
NCT06090266 · OncoResponse, Inc.
2023-10-24 – 2027-02-01 · Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
What this study did
NCT05882734 · EMD Serono Research & Development Institute, Inc.
2023-09-13 – 2026-07-15 · Non-Small Cell Lung Cancer
What this study did
NCT05864144 · Sensei Biotherapeutics, Inc.
2023-05-31 – 2026-06-02 · Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
What this study did
NCT05259696 · Palleon Pharmaceuticals, Inc.
2022-02-11 – 2024-10-24 · Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
What this study did
NCT05094804 · OncoResponse, Inc.
2021-09-09 – 2024-08-15 · Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
What this study did
NCT03367819 · Sanofi
2018-01-04 – 2021-03-10 · Prostate Cancer, Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07567469 · Regeneron Pharmaceuticals
2026-08-31 – 2034-08-17 · High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
What this study did
NCT07594106 · Regeneron Pharmaceuticals
2026-07-20 – 2030-10-27 · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT06412198 · M.D. Anderson Cancer Center
2024-08-28 – 2029-03-01 · Metastatic Colorectal Cancer, KRAS G12C Mutations
What this study did
NCT07251413 · Instituto Oncológico Dr Rosell
2025-10-22 – 2028-12 · Cutaneous Basal Cell Carcinoma
What this study did
NCT04989946 · University of Wisconsin, Madison
2021-12-16 – 2028-12 · Prostate Cancer
What this study did
NCT04590326 · Regeneron Pharmaceuticals
2020-12-08 – 2028-11-08 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
What this study did
NCT06923761 · Grey Wolf Therapeutics
2023-05-21 – 2028-04-30 · Advanced Solid Malignancy
What this study did
NCT06384807 · Biohaven Therapeutics Ltd.
2024-04-22 – 2028-02 · Solid Tumor
What this study did
NCT03491683 · Inovio Pharmaceuticals
2018-05-31 – 2027-12-31 · Glioblastoma
What this study did
NCT03972657 · Regeneron Pharmaceuticals
2019-08-12 – 2027-11-15 · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT04046107 · National Institute of Allergy and Infectious Diseases (NIAID)
2024-01-01 – 2027-09-30 · Hepatitis B Virus
What this study did
NCT07147231 · National Cancer Institute (NCI)
2026-08-10 – 2027-09-30 · Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
What this study did
NCT04305795 · Rakuten Medical, Inc.
2020-12-21 – 2027-06 · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
What this study did
NCT03564340 · Regeneron Pharmaceuticals
2018-05-21 – 2027-05-10 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
What this study did
NCT04626635 · Regeneron Pharmaceuticals
2020-12-21 – 2027-03-05 · Advanced Solid Tumors
What this study did
NCT05662397 · HotSpot Therapeutics, Inc
2023-03-15 – 2026-12-31 · Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
What this study did
NCT05538988 · AHS Cancer Control Alberta
2024-12 – 2026-03 · Mycosis Fungoides
What this study did
NCT04706715 · University Medical Center Groningen
2022-01-18 – 2025-11 · Metastatic Solid Tumor
What this study did
NCT04339062 · Dana-Farber Cancer Institute
2020-11-03 – 2025-03-01 · Cutaneous Squamous Cell Carcinoma, Advanced Cancer
What this study did
NCT04382898 · BioNTech SE
2019-12-19 – 2024-01-23 · Prostate Cancer
What this study did
NCT03690869 · Regeneron Pharmaceuticals
2018-09-24 – 2023-05-10 · Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
What this study did
NCT03194867 · Sanofi
2018-02-21 – 2023-04-05 · Plasma Cell Myeloma
What this study did
NCT03294083 · SillaJen, Inc.
2018-06-19 – 2023-02-16 · Renal Cell Carcinoma
What this study did
NCT03769181 · Sanofi
2018-12-11 – 2022-11-08 · Lymphoma
What this study did
NCT03787095 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-08-13 – 2020-08-18 · HIV Infections
What this study did
Phase 1 (44)
Melanoma
NCT06022029 · OncoNano Medicine, Inc.
2023-10-13 – 2026-08-29 · Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
What this study did
Non-Small Cell Lung Cancer
NCT06171750 · Ankyra Therapeutics, Inc
2024-01-19 – 2027-06 · Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
What this study did
NCT04982224 · Regeneron Pharmaceuticals
2021-11-09 – 2025-10-15 · Advanced NSCLC
What this study did
NCT06052852 · Bolt Biotherapeutics, Inc.
2023-10-11 – 2025-08-01 · Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
What this study did
NCT03580694 · Regeneron Pharmaceuticals
2018-06-27 – 2019-12-04 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT07365839 · Virginia Commonwealth University
2026-10-01 – 2035-05-28 · Hepatocellular Carcinoma
What this study did
NCT03017820 · Mayo Clinic
2017-04-04 – 2032-04-01 · B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
What this study did
NCT06508463 · Mayo Clinic
2024-01-05 – 2032-04-01 · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
What this study did
NCT04428671 · Emory University
2020-05-15 – 2031-10-01 · Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
What this study did
NCT07404332 · Mohammed Milhem
2026-02-11 – 2031-02-28 · Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
What this study did
NCT07650266 · Memorial Sloan Kettering Cancer Center
2026-12 – 2030-07 · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
What this study did
NCT06469281 · Regeneron Pharmaceuticals
2024-08-06 – 2030-05-27 · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
What this study did
NCT07869823 · Vanderbilt-Ingram Cancer Center
2026-09 – 2029-09 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT06826768 · M.D. Anderson Cancer Center
2025-07-09 – 2029-05-01 · Prostate Cancer
What this study did
NCT06874335 · Biohaven Therapeutics Ltd.
2025-03-20 – 2029-03 · Solid Tumor
What this study did
NCT06902376 · UNC Lineberger Comprehensive Cancer Center
2025-06-03 – 2028-08-31 · Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
What this study did
NCT05729139 · Baptist Health South Florida
2023-07 – 2028-07 · Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT04975152 · H. Lee Moffitt Cancer Center and Research Institute
2021-10-22 – 2028-03 · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
What this study did
NCT03233139 · Regeneron Pharmaceuticals
2017-06-21 – 2027-09-30 · Advanced Malignancies
What this study did
NCT04722523 · Memorial Sloan Kettering Cancer Center
2021-01-20 – 2027-06-20 · Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
What this study did
NCT05259709 · Regeneron Pharmaceuticals
2023-02-07 – 2027-04-29 · Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT07422363 · National Cancer Institute (NCI)
2026-12-04 – 2027-02-28 · Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma
What this study did
NCT06302426 · Inimmune Corporation
2024-07-01 – 2026-06-19 · Advanced Solid Tumor
What this study did
NCT02651662 · Regeneron Pharmaceuticals
2016-01-11 – 2026-04-29 · Relapsed/Refractory Aggressive B-Cell Lymphoma
What this study did
NCT03889912 · Regeneron Pharmaceuticals
2019-04-11 – 2025-12-10 · Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
What this study did
NCT05376553 · Krzysztof Misiukiewicz
2022-07-20 – 2025-10 · Locally Advanced Head and Neck Squamous Cell Carcinoma
What this study did
NCT05064085 · H. Lee Moffitt Cancer Center and Research Institute
2021-10-12 – 2025-03-13 · Hormone Receptor-positive Breast Cancer
What this study did
NCT04465487 · Regeneron Pharmaceuticals
2020-10-05 – 2025-02-07 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT05054348 · Immune-Onc Therapeutics
2021-09-30 – 2024-05-31 · Solid Tumor, Adult
What this study did
NCT03005782 · Regeneron Pharmaceuticals
2016-11-07 – 2024-04-02 · Malignancies
What this study did
NCT04826393 · Dana-Farber Cancer Institute
2022-03-09 – 2024-01-01 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT02520245 · Regeneron Pharmaceuticals
2015-08 – 2023-11 · Advanced Malignancies
What this study did
NCT04729725 · M.D. Anderson Cancer Center
2021-02-09 – 2022-12-02 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
What this study did
NCT04460456 · Silverback Therapeutics
2020-07-27 – 2022-12 · HER2 Positive Solid Tumors
What this study did
NCT03198130 · Regeneron Pharmaceuticals
2017-07-03 – 2020-02-21 · Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck, Metastatic Squamous Cell Carcinoma of Head, Metastatic Squamous Cell Carcinoma Neck
What this study did
NCT02383212 · Regeneron Pharmaceuticals
2015-02-02 – 2019-11-18 · Advanced Cancer, Advanced Malignancies
What this study did
NCT03477864 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2018-12-24 – 2019-11-04 · Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT06743581 · Centre hospitalier de l'Université de Montréal (CHUM)
2025-08-19 – 2030-02 · Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT05317858 · InSightec
2022-08-12 – 2031-12-01 · Brain Tumor, Non Small Cell Lung Cancer
What this study did
Phase 2 (6)
Non-Small Cell Lung Cancer
NCT07020065 · Swiss Cancer Institute
2026-04-10 – 2030-09 · Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
Other / comorbidity
NCT07223541 · University of Oklahoma
2026-01-15 – 2031-08 · Clear Cell Renal Cell Carcinoma
What this study did
NCT04050436 · Replimune, Inc.
2019-10-08 – 2025-09 · Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
What this study did
NCT03669718 · ISA Pharmaceuticals
2018-11-30 – 2025-06 · Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT06162572 · Servier Bio-Innovation LLC
2024-08-07 – 2027-07 · Non-small Cell Lung Cancer (NSCLC)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Melanoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cemiplimab: this drugPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(119 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cemiplimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
Phase 2Prostate Cancer MetastaticActive not recruiting
Est. primary completion 2026-11 · NCT03951831 · CT.gov ↗
What to watch
December 2026 (4)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2026-12 · NCT04989946 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06623656 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗
What to watch
Phase 2Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer …Active not recruiting
Est. primary completion 2026-12-31 · NCT04315701 · CT.gov ↗
What to watch
2027 (35)
January 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-01-15 · NCT05608291 · CT.gov ↗
What to watch
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the LiverRecruiting
Est. primary completion 2027-01-30 · NCT06860815 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 GliomaNot yet recruiting
Est. primary completion 2027-02-28 · NCT07422363 · CT.gov ↗
What to watch
March 2027 (2)
Phase 3MelanomaRecruiting
Est. primary completion 2027-03-22 · NCT06246916 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04 · NCT06171750 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, Metastatic Solid TumorActive not recruiting
Est. primary completion 2027-04-29 · NCT05259709 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid MalignancyActive not recruiting
Est. primary completion 2027-04-30 · NCT06923761 · CT.gov ↗
What to watch
Phase 2Colon CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT05961709 · CT.gov ↗
What to watch
May 2027 (3)
Phase 1Prostate CancerRecruiting
Est. primary completion 2027-05-01 · NCT06826768 · CT.gov ↗
What to watch
Phase 1/2Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer …Recruiting
Est. primary completion 2027-05-10 · NCT03564340 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Oral Cavity Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-15 · NCT06448026 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCCRecruiting
Est. primary completion 2027-06-20 · NCT04722523 · CT.gov ↗
What to watch
Phase 2HPV-Related Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT04988074 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary CarcinomaRecruiting
Est. primary completion 2027-07-31 · NCT06444880 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-31 · NCT06908304 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT06865339 · CT.gov ↗
What to watch
September 2027 (6)
Phase 2MelanomaRecruiting
Est. primary completion 2027-09 · NCT06594991 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-28 · NCT05785767 · CT.gov ↗
What to watch
Phase 1Advanced MalignanciesActive not recruiting
Est. primary completion 2027-09-30 · NCT03233139 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 …Recruiting
Est. primary completion 2027-09-30 · NCT07147231 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT05208944 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10 · NCT07264673 · CT.gov ↗
What to watch
Phase 2Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-10-06 · NCT05574101 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1/2Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2027-11-15 · NCT03972657 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-11-24 · NCT06980038 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT06449313 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT06743581 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07450183 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03491683 · CT.gov ↗
What to watch
Phase 2Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck …Active not recruiting
Est. primary completion 2027-12-31 · NCT03565783 · CT.gov ↗
What to watch
Phase 2Leiomyosarcoma, SarcomaRecruiting
Est. primary completion 2027-12-31 · NCT06528769 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
2028 (33)
January 2028 (4)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT05704634 · CT.gov ↗
What to watch
Phase 3Cutaneous Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-07 · NCT03969004 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-26 · NCT05557591 · CT.gov ↗
What to watch
February 2028 (3)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2028-02 · NCT06384807 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-02 · NCT06699602 · CT.gov ↗
What to watch
Phase 1Solid Tumor, Locally Advanced Solid Tumor, Metastatic TumorRecruiting
Est. primary completion 2028-02-28 · NCT07404332 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1Merkel Cell Carcinoma, Cutaneous Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-03 · NCT04975152 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-03 · NCT06855212 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 1Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related TumorsRecruiting
Est. primary completion 2028-03-31 · NCT06902376 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma …Active not recruiting
Est. primary completion 2028-04-07 · NCT05694871 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-05 · NCT07418931 · CT.gov ↗
What to watch
Phase 2Pleural MesotheliomasRecruiting
Est. primary completion 2028-05 · NCT07234058 · CT.gov ↗
What to watch
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-05-24 · NCT07511036 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Pancreatic Cancer, Adenocarcinoma of the Pancreas, AdenocarcinomaActive not recruiting
Est. primary completion 2028-06 · NCT04543071 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)Recruiting
Est. primary completion 2028-06-04 · NCT06769698 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerRecruiting
Est. primary completion 2028-06-30 · NCT06787612 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Adrenal Cortical CarcinomaRecruiting
Est. primary completion 2028-07 · NCT07085572 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (mPDAC)Recruiting
Est. primary completion 2028-07 · NCT06790602 · CT.gov ↗
What to watch
September 2028 (3)
Phase 1Cutaneous Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-09 · NCT07869823 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT06656598 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-09-01 · NCT06651593 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Basal Cell Carcinoma (BCC), First Line TreatmentRecruiting
Est. primary completion 2028-10 · NCT06981325 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-30 · NCT06385262 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1/2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial CancerRecruiting
Est. primary completion 2028-11-08 · NCT04590326 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (6)
Phase 1/2Cutaneous Basal Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07251413 · CT.gov ↗
What to watch
Phase 2Vulvar CancersNot yet recruiting
Est. primary completion 2028-12 · NCT07101848 · CT.gov ↗
What to watch
Phase 2Penile CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07101822 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07360743 · CT.gov ↗
What to watch
Phase 1B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-12-31 · NCT03017820 · CT.gov ↗
What to watch
Phase 1Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified …Recruiting
Est. primary completion 2028-12-31 · NCT06508463 · CT.gov ↗
What to watch
2029 (15)
February 2029 (1)
Phase 2MelanomaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07527325 · CT.gov ↗
What to watch
March 2029 (3)
Phase 1Solid TumorRecruiting
Est. primary completion 2029-03 · NCT06874335 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03 · NCT06931717 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, KRAS G12C MutationsRecruiting
Est. primary completion 2029-03-01 · NCT06412198 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Colo-rectal CancerRecruiting
Est. primary completion 2029-04-17 · NCT07058012 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin CancerActive not recruiting
Est. primary completion 2029-05 · NCT05878288 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07946848 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma …Recruiting
Est. primary completion 2029-06-02 · NCT06900595 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Head and Neck CancerRecruiting
Est. primary completion 2029-11-30 · NCT07179315 · CT.gov ↗
What to watch
Phase 2Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2029-11-30 · NCT07188896 · CT.gov ↗
What to watch
December 2029 (5)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07808138 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-12-04 · NCT06465329 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07274384 · CT.gov ↗
What to watch
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07224022 · CT.gov ↗
What to watch
Phase 2Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant ImmunotherapyRecruiting
Est. primary completion 2029-12-31 · NCT07387198 · CT.gov ↗
What to watch
2030 (22)
January 2030 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01 · NCT06219317 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01-16 · NCT05800015 · CT.gov ↗
What to watch
February 2030 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-02 · NCT05142189 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-02-03 · NCT06413680 · CT.gov ↗
What to watch
May 2030 (3)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-05 · NCT06205836 · CT.gov ↗
What to watch
Phase 3Cutaneous Squamous Cell Carcinoma (CSCC)Recruiting
Est. primary completion 2030-05-03 · NCT06585410 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube CancerRecruiting
Est. primary completion 2030-05-27 · NCT06469281 · CT.gov ↗
What to watch
July 2030 (3)
Phase 1Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx CancerNot yet recruiting
Est. primary completion 2030-07 · NCT07650266 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-07 · NCT07281768 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-07-30 · NCT06418724 · CT.gov ↗
What to watch
September 2030 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09 · NCT07001618 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09-01 · NCT07746388 · CT.gov ↗
What to watch
Phase 2Anaplastic Thyroid CancerRecruiting
Est. primary completion 2030-09-01 · NCT07470489 · CT.gov ↗
What to watch
October 2030 (4)
Phase 1Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2030-10-01 · NCT04428671 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2030-10-09 · NCT06848088 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2030-10-27 · NCT07594106 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2030-10-31 · NCT06121180 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Locally Advanced Basal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-11-13 · NCT07808515 · CT.gov ↗
What to watch
Phase 2Metastatic NUT Carcinoma, Unresectable NUT CarcinomaRecruiting
Est. primary completion 2030-11-20 · NCT07050186 · CT.gov ↗
What to watch
December 2030 (3)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-12-02 · NCT06918132 · CT.gov ↗
What to watch
Phase 2Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8 …Recruiting
Est. primary completion 2030-12-16 · NCT07281417 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 2Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney TransplantNot yet recruiting
Est. primary completion 2031-04-30 · NCT07715734 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeNot yet recruiting
Est. primary completion 2031-05-31 · NCT07620548 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2031-08-22 · NCT07346196 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-12-30 · NCT06917573 · CT.gov ↗
What to watch
2032 (3)
January 2032 (1)
Phase 2Colon and Rectal CancerRecruiting
Est. primary completion 2032-01 · NCT07433673 · CT.gov ↗
What to watch
February 2032 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-02 · NCT07943325 · CT.gov ↗
What to watch
August 2032 (1)
Phase 1/2High-Grade Glioma (HGG), Posterior Fossa-A EpendymomaNot yet recruiting
Est. primary completion 2032-08-27 · NCT07567469 · CT.gov ↗
What to watch
2033 (1)
February 2033 (1)
Phase 2Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 …Recruiting
Est. primary completion 2033-02-01 · NCT07195734 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2035-08-01 · NCT07720167 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

March 2027FDA action dateFDA decision on the Libtayo alternative-dosing sBLA expected March 2027
US, FDA · Source ↗

Recent

17 November 2026ApprovalEuropean Commission approves an extended Libtayo dosing schedule (700 mg every six weeks) and shorter infusion
EU, European Commission · Source ↗
17 May 2026Topline resultPhase 3 of fianlimab plus cemiplimab vs pembrolizumab in first-line melanoma (NCT05352672) missed its PFS primary endpoint